This study evaluated a newly identified acetyl group recognition receptor, FIBCD1, as a novel biomarker to evaluate the prognosis of gastric cancer.
American Journal of Clinical Pathology
Original Article: FIBCD1 Predicts Poor Prognosis in Gastric Cancer